| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 | SCHEDULE 13G |
| 02 Nov 2026 |
Form 4: Ewald Stephen P, General Counsel & Corp. Secy.
Sold 1,245 shares ($859K) |
| 29 Oct 2026 | 144 |
| 28 Oct 2026 |
Form 4: Burwig Susan E, Exec. VP, Operations
Sold 16,060 shares ($10.9M) · Received 328 shares by exercise or conversion ($54.7K) · Sold 3,940 shares ($2.67M) |
| 27 Oct 2026 | 144 |
| 26 Oct 2026 | 144 |
| 23 Oct 2026 |
Form 4: Burwig Susan E, Exec. VP, Operations
Received 2,700 shares by exercise or conversion ($450K) |
| 22 Oct 2026 | 10-Q |
| 21 Oct 2026 |
8-K: Results of Operations and Financial Condition; Other Events
CINCINNATI, OHIO, October 21, 2026-- Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the third quarter ended September 30, 2026. |
| 14 Oct 2026 |
Form 4: Burwig Susan E, Exec. VP, Operations
Received 3,000 shares by exercise or conversion ($500K) |
| 09 Oct 2026 |
Form 4: Burwig Susan E, Exec. VP, Operations
Received 2,000 shares by exercise or conversion ($333K) |
| 02 Oct 2026 |
Form 4: McCarthy Cornelius P. Iii, Director
Received 28 shares by exercise or conversion |
| 02 Oct 2026 |
Form 4: Kraft Robert O., Director
Received 32 shares by exercise or conversion |
| 02 Oct 2026 |
Form 4: Carley Brian T, Director
Received 36 shares by exercise or conversion |
| 01 Oct 2026 |
Form 4: Troendle August J., Director
Sold 26,701 shares ($16.6M) · Sold 21,966 shares ($13.7M) |
| 29 Sep 2026 |
Form 4: Troendle August J., Director
Sold 154 shares ($95.6K) · Sold 2,410 shares ($1.49M) |
| 28 Sep 2026 | SCHEDULE 13D/A |
| 25 Sep 2026 |
Form 4: Troendle August J., Director
Sold 16,083 shares ($10.1M) · Sold 27,833 shares ($17.3M) |
| 23 Sep 2026 |
Form 4: Troendle August J., Director
Sold 21,883 shares ($13.6M) · Sold 49,018 shares ($30.8M) |
Loading...